<unk>  has been reported as a substrate for the OATP1B1 and OATP1B3 transporters. Interaction of<unk>  with OATP1B1 and OATP1B3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. Also,<unk>  is an inhibitor of OATP1B3 transporter but not for OATP1B1. Other drugs that prolong the QT interval can possibly add to this side effect of<unk> . As the drug is partly metabolised via the liver enzyme CYP3A4, strong inducers of this enzyme can decrease its blood plasma concentrations. CYP3A4 inhibitors do not significantly increase<unk>  concentrations, presumably because it is also metabolised by flavin containing monooxygenase 1 (FMO1) and 3.
Vandetanib
Selepressin
Masitinib
Vatalanib
Alectinib
Pegaptanib
Enasidenib
Tivozanib